From "Individual Partnerships" to "Whole-Course Management": China's role in global innovation deepens
If the shift from "first showcase" to "first launch" reflects the speed at which innovation lands, the research outcomes and innovation partnerships released this year show another, more pronounced change: China is not only an application market for global innovation, but is also increasingly involved in innovation itself.
During the CIIE, Bayer held dozens of signing ceremonies, achievement releases, and exchange events with partners spanning government, healthcare, research institutions, and industry associations. A series of collaborations has extended from single products and one-off projects toward scientific evidence, clinical practice, whole-course management, primary-care services, and industry synergy.
At the source of innovation, China's participation in global innovation is deepening. For Sunharbo, Bayer further presented during the CIIE the contribution of Chinese patients and investigators to the global Phase III study, together with data from the Chinese population, highlighting the role of Chinese evidence in global R&D.
Data and artificial intelligence are also moving further into clinical innovation. Bayer and the Eye Hospital of Wenzhou Medical University formally signed a letter of intent on data collaboration. The two parties will focus on the compliant circulation and innovative application of high-quality healthcare data on retinal diseases, leveraging their respective strengths in clinical research and pharmaceutical innovation to explore new paths for data-driven ophthalmic research and innovation.
